Dr. Raid Aljumaily
Claim this profileUniversity of Oklahoma Health Sciences Center
Expert in Non-Small Cell Lung Cancer
Expert in Lung Cancer
24 reported clinical trials
40 drugs studied
About Raid Aljumaily
Education:
- Graduated with an MD from the University of Baghdad College of Medicine, Iraq, in 2009.
- Completed a Residency in Internal Medicine at the University of Oklahoma Health Sciences Center in 2016.
- Finished a Fellowship in Hematology/Oncology at the University of Oklahoma Health Sciences Center in 2019.
Experience:
- Has been serving as an Assistant Professor of Medicine at the University of Oklahoma Health Sciences Center since 2019.
- Specializes in hematologic malignancies, lymphoma, and myelodysplastic syndromes.
Area of expertise
1Non-Small Cell Lung Cancer
Global LeaderStage IV
Stage III
Stage II
2Lung Cancer
Global LeaderStage IV
Stage III
Stage II
Affiliated Hospitals
Clinical Trials Raid Aljumaily is currently running
Osimertinib + Bevacizumab
for Lung Cancer
This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Monoclonal antibodies, such as bevacizumab, may interfere with the ability of tumor cells to grow and spread. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.
Recruiting2 awards Phase 331 criteria
Monalizumab or Oleclumab with Durvalumab and Radiation
for Lung Cancer
This phase I trial studies the safety of adding durvalumab to accelerated hypofractionated radiation therapy (ACRT) or conventionally fractionated radiation therapy, as well as the safety of adding either monalizumab or oleclumab to durvalumab plus conventionally fractionated radiation therapy in treating patients with non-small cell lung cancer that has spread to nearby tissue or lymph nodes (locally advanced). Accelerated hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and have fewer side effects. Immunotherapy with monoclonal antibodies, such as durvalumab and monalizumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Oleclumab is in a class of medications called monoclonal antibodies. It binds to a protein called CD73, which is found on some types of tumor cells. Oleclumab may block CD73 and help the immune system kill tumor cells. It is not yet known whether adding durvalumab to ACRT or adding monalizumab or oleclumab to durvalumab plus conventionally fractionated radiation therapy will work better in treating patients with non-small cell lung cancer.
Recruiting1 award Phase 110 criteria
More about Raid Aljumaily
Clinical Trial Related7 years of experience running clinical trials · Led 24 trials as a Principal Investigator · 17 Active Clinical TrialsTreatments Raid Aljumaily has experience with
- Pembrolizumab
- Carboplatin
- Pemetrexed
- Paclitaxel
- Nivolumab
- Atezolizumab
Breakdown of trials Raid Aljumaily has run
Non-Small Cell Lung Cancer
Lung Cancer
Cancer
Lung Carcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Raid Aljumaily specialize in?
Raid Aljumaily focuses on Non-Small Cell Lung Cancer and Lung Cancer. In particular, much of their work with Non-Small Cell Lung Cancer has involved Stage IV patients, or patients who are Stage III.
Is Raid Aljumaily currently recruiting for clinical trials?
Yes, Raid Aljumaily is currently recruiting for 17 clinical trials in Oklahoma City Oklahoma. If you're interested in participating, you should apply.
Are there any treatments that Raid Aljumaily has studied deeply?
Yes, Raid Aljumaily has studied treatments such as Pembrolizumab, Carboplatin, Pemetrexed.
What is the best way to schedule an appointment with Raid Aljumaily?
Apply for one of the trials that Raid Aljumaily is conducting.
What is the office address of Raid Aljumaily?
The office of Raid Aljumaily is located at: University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73104 United States. This is the address for their practice at the University of Oklahoma Health Sciences Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.